Molecules Engineered Against Oncogenic Proteins and Cancer

Molecules Engineered Against Oncogenic Proteins and Cancer

A comprehensive review of the latest molecular advances in cancer treatment

Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine’s most challenging areas—cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented.

With a very well-known chemist as an author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on:

• Each molecule’s structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action
• Mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent
• History of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer
• The discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field

Combining the most significant recent discoveries in a unique and useful way, Molecules Engineered Against Oncogenic Proteins and Cancer is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology as well as for those at industrial companies involved in therapeutic discovery.